In its third-quarter report, Amarin (NASDAQ: AMRN) topped FactSet's consensus revenue estimate ($112.4 million versus $110.04 million) and non-GAAP adjusted earnings-per-share forecast ($0.01, versus a $0.04 loss). Even so, Amarin's shares still hit the skids during Tuesday's trading session. Specifically, the biopharma's stock sank by as much as 6.3% on heavy volume, before rebounding to finish down by a more modest 0.69%.
Should investors take advantage of this post-earnings weakness, or is it better to stick the sidelines with this high-risk, high-reward biopharma stock? Let's dissect Amarin's near- and long-term outlook to find out.
Image source: Getty Images.